{"entity":{"id":"ncc-hospital-east","kind":"institution","name":"National Cancer Center Hospital East","aka":["NCCHE","国立がん研究センター東病院"],"tldr":"National Cancer Center Hospital East in Kashiwa is one of the world's most productive trial sites for gastrointestinal, thoracic and head and neck cancer; it runs the SCRUM-Japan genomic screening platform, a large phase 1 unit and one of Japan's first hospital-based proton facilities.","summary":"NCC Hospital East opened in 1992 in Kashiwa as the second hospital of the National Cancer Center and has become one of the most productive trial sites in the world for gastrointestinal, thoracic and head and neck cancer. It hosts the Exploratory Oncology Research and Clinical Trial Center (EPOC), a large phase 1 unit, one of Japan's first hospital-based proton therapy facilities, and the SCRUM-Japan nationwide genomic screening platform (GI-SCREEN, LC-SCRN, MONSTAR-SCREEN, CIRCULATE-Japan) led by Takayuki Yoshino. Kohei Shitara and Toshihiko Doi have led pivotal gastric and oesophageal cancer trials of trastuzumab deruxtecan, zolbetuximab and nivolumab, and Koichi Goto's thoracic group has led ALK, ROS1 and RET programmes. The campus includes the National Cancer Center's photoimmunotherapy and surgical innovation groups.","asOf":"2026-09-09","links":[{"label":"NCC Hospital East","url":"https://www.ncc.go.jp/en/ncce/"},{"label":"SCRUM-Japan","url":"https://www.scrum-japan.ncc.go.jp"},{"label":"PTCOG: particle therapy facilities in operation","url":"https://www.ptcog.site/index.php/facilities-in-operation-public"}],"tags":[],"related":[],"cancers":["gastric","esophageal","colorectal","nsclc","head-and-neck"],"sections":["targeted-therapy","radiation","diagnostics"],"technologies":["proton-therapy","cgp","liquid-biopsy","mrd-testing","photoimmunotherapy","proton-therapy-systems"],"targets":["her2","cldn18-2","ret","alk"],"drugs":["trastuzumab-deruxtecan","nivolumab"],"companies":["jcog"],"institutions":["ncc-japan"],"pathways":[],"terms":["ctdna","mrd"],"trials":[],"people":["yoshino-takayuki","shitara-kohei","doi-toshihiko","goto-koichi"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Kashiwa, Chiba","country":"JP","lat":35.878,"lng":139.935,"institutionType":"cancer-center","website":"https://www.ncc.go.jp/en/ncce/","programs":["SCRUM-Japan and CIRCULATE-Japan","Phase 1 (EPOC)","Gastric and oesophageal cancer trials","Proton therapy","Photoimmunotherapy"]},"route":"/institutions/ncc-hospital-east/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/"}],"section":[{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/"},{"id":"radiation","kind":"section","name":"Radiation Therapy","route":"/fronts/radiation/"},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"cgp","kind":"technology","name":"Comprehensive genomic profiling","route":"/technologies/cgp/"},{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"},{"id":"photoimmunotherapy","kind":"technology","name":"Photoimmunotherapy & photodynamic therapy","route":"/technologies/photoimmunotherapy/"},{"id":"proton-therapy","kind":"technology","name":"Proton therapy","route":"/technologies/proton-therapy/"},{"id":"proton-therapy-systems","kind":"technology","name":"Proton therapy machines: cyclotrons, synchrotrons and single-room systems","route":"/technologies/proton-therapy-systems/"}],"target":[{"id":"alk","kind":"target","name":"ALK","route":"/targets/alk/"},{"id":"cldn18-2","kind":"target","name":"Claudin 18.2","route":"/targets/cldn18-2/"},{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"},{"id":"ret","kind":"target","name":"RET","route":"/targets/ret/"}],"drug":[{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/"}],"company":[{"id":"jcog","kind":"company","name":"Japan Clinical Oncology Group (JCOG)","route":"/companies/jcog/"}],"institution":[{"id":"ncc-japan","kind":"institution","name":"National Cancer Center Hospital","route":"/institutions/ncc-japan/"}],"term":[{"id":"ctdna","kind":"term","name":"Circulating tumour DNA (ctDNA)","route":"/terms/ctdna/"},{"id":"mrd","kind":"term","name":"Minimal / molecular residual disease (MRD)","route":"/terms/mrd/"}],"person":[{"id":"shitara-kohei","kind":"person","name":"Kohei Shitara","route":"/people/shitara-kohei/"},{"id":"goto-koichi","kind":"person","name":"Koichi Goto","route":"/people/goto-koichi/"},{"id":"yoshino-takayuki","kind":"person","name":"Takayuki Yoshino","route":"/people/yoshino-takayuki/"},{"id":"doi-toshihiko","kind":"person","name":"Toshihiko Doi","route":"/people/doi-toshihiko/"}]}}